Prof. dr. A.P. Kater MD PhD publications

foto

Publications Prof. dr. A.P. Kater MD PhD

Main activities
Patient care, Research, Teaching
Focus of research

Research focus on biology and treatment of B-cell malignancies with chronic lymphocytic leukemia (CLL) as main disease serving as a B-cell malignancy model.

Research involves both pre-clinical (cellines, primary CLL cells, mouse models) as well as clinical (phase 1, 2, 3) studies.

The studies are divided in three reserach programs around the central theme: development of, circumvention of and novel strategies for (development of) chemorefractory disease

1. Genetic abberations

2. Intracellular signaling

3. Cross-talk with microenvironment

2018

  • Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadhi S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ, Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. LANCET HAEMATOL 2018;5 (4):e170-e180 [PubMed]
  • de Back TR, Kater AP, Tonino SH, Autoimmune cytopenias in chronic lymphocytic leukemia: a concise review and treatment recommendations. EXPERT REV HEMATOL 2018;11 (8):613-624 [PubMed]
  • de Weerdt I, Hofland T, Lameris R, Endstra S, Jongejan A, Moerland P, de Bruin RCG, Remmerswaal EBM, ten Berge IJM, Liu N, van der Stelt M, Faber LM, Levin MD, Eldering E, Tonino SH, de Gruijl TD, van der Vliet HJ, Kater AP, Improving CLL V gamma 9V delta 2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib. BLOOD 2018;132 (21):2260-2272 [PubMed]
  • Dinmohamed AG, Posthuma EFM, Visser O, Kater AP, Raymakers RAP, Doorduijn JK, Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in The Netherlands. BLOOD 2018;131 (12):1380-1383 [PubMed]
  • Kater AP, Brown JR, Ibrutinib: searching for a partner drug. LANCET ONCOL 2018;ahead of print [PubMed]
  • Kater AP, Kersting S, van Norden Y, Dubois J, Dobber JA, Mellink CH, Evers LM, Croon-de Boer F, Schreurs J, van der Spek E, Visser H, Idink C, Wittebol S, Hoogendoorn M, Tonino SH, Mobasher M, Levin MD, Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. BLOOD ADV 2018;2 (24):3566-3571 [PubMed]
  • Kater AP, Tonino SH, Spiering M, Chamuleau MED, Liu R, Adewoye AH, Gao J, Dreiling L, Xin Y, Doorduijn JK, Kersten MJ, Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies. BLOOD CANCER J 2018;8 (2):16 [PubMed]
  • Kater AP, van Oers MHJ, van Norden Y, van der Straten L, Driessen J, Posthuma WFM, Schipperus M, Chamuleau MED, Nijland M, Doorduijn JK, van Gelder M, Hoogendoorn M, de Croon F, Wittebol S, Kerst JM, Marijt EWA, Raymakers RAP, Schaafsma MR, Dobber JA, Kersting SA, Levin MD, Feasibility and efficacy of addition of individualized dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia. HAEMATOLOGICA 2018;ahead of print [PubMed]
  • Kersting S, Neppelenbroek SIM, Visser HPJ, van Gelder M, Levin MD, Mous R, Posthuma W, van der Straaten HM, Kater AP, Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands. CL LYMPH MYELOM LEUK 2018;18 (1):52-57 [PubMed]
  • Leeksma AC, Taylor J, Wu B, Gardner JR, He J, Nahas M, Gonen M, Alemayehu WG, te Raa D, Walther T, Hüllein J, Dietrich S, Claus R, de Boer F, de Heer K, Dubois J, Dampmann M, Dürig J, van Oers MHJ, Geisler CH, Eldering E, Levine RL, Miller V, Mughal T, Lamanna N, Frattini MG, Heaney ML, Zelenetz A, Zenz T, Abdel-Wahab O, Kater AP, Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. LEUKEMIA 2018;ahead of print [PubMed]
  • Malcikova J, Tausch E, Rossi D, Sutton LA, Soussi T, Zenz T, Kater AP , Niemann CU, Gonzalez D, Davi F, Gonzalez Diaz M, Moreno C, Gaidano G, Stamatopoulos K, Rosenquist R, Stilgenbauer S, Ghia P, Pospisilova S, ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. LEUKEMIA 2018;32 (5):1070-1080 [PubMed]
  • Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP, Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. NEW ENGL J MED 2018;378 (12):1107-1120 [PubMed]
  • Seymour JF, Mobasher M, Kater AP, Venetoclax-Rituximab in Chronic Lymphocytic Leukemia REPLY. NEW ENGL J MED 2018;378 (22):2143-+ [PubMed]
  • van der Straten L, Dinmohamed AG, Westerweel PE, Langerak AW, Riedl J, Doorduijn JK, Kater AP, Levin MD, Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy. LEUKEMIA LYMPHOMA 2018;ahead of print [PubMed]
  • Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W, Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. LANCET 2018;391 (10121):659-667 [PubMed]

2017

  • de Weerdt I, Koopmans SM, Kater AP, van Gelder M, Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. HAEMATOLOGICA 2017;102 (10):1629-1639 [PubMed]
  • Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, Ghia P, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M, Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. LANCET HAEMATOL 2017;4 (10):e475-e486 [PubMed]
  • Singh SP, Pillai SY, de Bruijn MJW, Stadhouders R, Corneth OBJ, van den Ham HJ, Muggen A, van Ijcken W, Slinger E, Kuil A, Spaargaren M, Kater AP, Langerak AW, Hendriks RW, Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling. ONCOTARGET 2017;8 (42):71981-71995 [PubMed]
  • Slinger E, Thijssen R, Kater AP , Eldering E, Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition. LEUKEMIA 2017;31 (12):2601-2607 [PubMed]
  • van Attekum MHA. Formation of a tumor-supportive microenvironment in chronic lymphocytic leukemia: Addressing the reciprocal interactions in the CLL—T cell—macrophage triad. S.l.: s.n.; 2017. 160p. ISBN 978-94-6182-754-8 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Eldering EF, Kater AP; copromotor(s): )
  • van Attekum MHA, Terpstra S, Slinger E, von Lindern M, Moerland PD, Jongejan A, Kater AP , Eldering E, Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia. ONCOGENE 2017;36 (26):3651-3660 [PubMed]
  • van Attekum MHA, van Bruggen JAC, Slinger E, Lebre MC, Reinen E, Kersting S, Eldering E, Kater AP, CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis. HAEMATOLOGICA 2017;102 (12):2069-2076 [PubMed]
  • van Attekum MH, Eldering E, Kater AP, Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk. HAEMATOLOGICA 2017;102 (9):1469-1476 [PubMed]
  • van der Valk M, Zaaijer HL, Kater AP, Schinkel J, Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection. J HEPATOL 2017;66 (1):242-243 [PubMed]

2016

  • de Weerdt I, van Hoeven V, Munneke JM, Endstra S, Hofland T, Hazenberg MD, Kater AP, Innate lymphoid cells are expanded and functionally altered in chronic lymphocytic leukemia. HAEMATOLOGICA 2016;101 (11):e461-e464 [PubMed]
  • Heijink DM, Kater AP , Hazenberg MD, Hagenbeek A, Kersten MJ, T-cells fighting B-cell lymphoproliferative malignancies: the emerging field of CD19 CAR T-cell therapy. NETH J MED 2016;74 (4):147-151 [PubMed]
  • Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP , Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P, A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. LEUKEMIA 2016;30 (4):929-936 [PubMed]
  • Siska PJ, van der Windt GJW, Kishton RJ, Cohen S, Eisner W, MacIver NJ, Kater AP, Weinberg JB, Rathmell JC, Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia. J IMMUNOL 2016;197 (6):2532-2540 [PubMed]
  • Slinger E, Wensveen FM, Guikema JE, Kater AP, Eldering E, Chronic lymphocytic leukemia development is accelerated in mice with deficiency of the pro-apoptotic regulator NOXA. HAEMATOLOGICA 2016;101 (9):e374-e377 [PubMed]
  • Stevens WBC, Netea MG, Kater AP, van der Velden WJFM, 'Trained immunity': consequences for lymphoid malignancies. HAEMATOLOGICA 2016;101 (12):1460-1468 [PubMed]
  • te Raa GD, Kater AP, TP53 dysfunction in CLL: Implications for prognosis and treatment. BEST PRACT RES CL HA 2016;29 (1):90-99 [PubMed]
  • Thijssen R. The interplay between microenvironmental signaling and novel targeted drugs in CLL. S.l.: s.n.; 2016. 171p. ISBN 978-94-6182-733-3 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Eldering EF, Kater AP; copromotor(s): Kersten MJ)
  • Thijssen R, ter Burg J, Garrick B, van Bochove GGW, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IAM, van Kampen RJW, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP, Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. BLOOD 2016;128 (4):574-583 [PubMed]
  • Thijssen R, ter Burg J, van Bochove GGW, de Rooij MFM, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MHJ, Eldering E, Kersten MJ , Kater AP, The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. LEUKEMIA 2016;30 (2):337-345 [PubMed]
  • Thijssen R, ter Burg J, van Bochove GGW, de Rooij MFM, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MHJ, Eldering E, Kersten MJ , Kater AP, The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 ( voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells (Vol 30, pg 337, 2016). LEUKEMIA 2016;30 (9):1963 [PubMed]
  • van Attekum MHA, Kater AP , Eldering E, The APRIL paradox in normal versus malignant B cell biology. CELL DEATH DIS 2016;7 (6):e2276 [PubMed]
  • van Attekum MHA, Terpstra S, Reinen E, Kater AP , Eldering E, Macrophage-mediated chronic lymphocytic leukemia cell survival is independent of APRIL signaling. CELL DEATH DISCOV 2016;2:16020 [PubMed]
  • van Gelder M, van Oers MH, Alemayehu WG, Abrahamse-Testroote MCJ, Cornelissen JJ, Chamuleau ME, Zachée P, Hoogendoorn M, Nijland M, Petersen EJ, Beeker A, Timmers GJ, Verdonck L, Westerman M, de Weerdt O, Kater AP, Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study. BONE MARROW TRANSPL 2016;51 (6):799-806 [PubMed]
  • [Contributors: Kersting S, Levin MD, Chamuleau M, Daenen SMGJ, Dompeling EC, Doorduijn JK, van Gelder M, Hoogendoorn M, Kerst JM, Nijland M, Nijziel MR, Posthuma EFM, Raymakers RAP, Schaafsma MR, Silbermann MH, van der Straaten HM, Veelken JH, Vos JMI, Wittebol S, van Oers MHJ, Kater AP]] , Dutch guidelines for the diagnosis and treatment of chronic lymphocytic leukaemia. NETH J MED 2016;74 (2):68-74 [PubMed]

2015

  • Blume CJ, Hotz-Wagenblatt A, Hüllein J, Sellner L, Jethwa A, Stolz T, Slabicki M, Lee K, Sharathchandra A, Benner A, Dietrich S, Oakes CC, Dreger P, te Raa D, Kater AP , Jauch A, Merkel O, Oren M, Hielscher T, Zenz T, p53-dependent non-coding RNA networks in chronic lymphocytic leukemia. LEUKEMIA 2015;29 (10):2015-2023 [PubMed]
  • de Rooij MFM, Kuil A, Kater AP, Kersten MJ, Pals ST, Spaargaren M, Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. BLOOD 2015;125 (14):2306-2309 [PubMed]
  • Kater AP, Lanasa MC, Wesselmann J, Fischer K, The 8th Young Investigators' Meeting on Chronic Lymphocytic Leukemia. LEUKEMIA LYMPHOMA 2015;56 (5):1556-1559 [PubMed]
  • Kater AP, van der Windt GJW, PD-L1 blockade: rejuvenating T cells in CLL. BLOOD 2015;126 (2):126-128 [PubMed]
  • Spaargaren M, de Rooij MFM, Kater AP , Eldering E, BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future. ONCOGENE 2015;34 (19):2426-2436 [PubMed]
  • te Raa GD. Molecular characteristics and prognosis in CLL. S.l.: s.n.; 2015. 240p. ISBN 978-94-6182-531-5 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Oers MHJ, Eldering EF; copromotor(s): Kater AP)
  • te Raa GD, Derks IAM, Navrkalova V, Skowronska A, Moerland PD, van Laar J, Oldreive C, Monsuur H, Trbusek M, Malcikova J, Lodén M, Geisler CH, Hüllein J, Jethwa A, Zenz T, Pospisilova S, Stankovic T, van Oers MHJ, Kater AP , Eldering E, The impact of SF3B1 mutations in CLL on the DNA-damage response. LEUKEMIA 2015;29 (5):1133-1142 [PubMed]
  • te Raa GD, Moerland PD, Leeksma AC, Derks IA, Yigittop H, Laddach N, Loden-van Straaten M, Navrkalova V, Trbusek M, Luijks DM, Zenz T, Skowronska A, Hoogendoorn M, Stankovic T, van Oers MH, Eldering E, Kater AP, Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification. CELL DEATH DIS 2015;6:e1852 [PubMed]
  • Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MHJ, Kater AP, Eldering E, Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. HAEMATOLOGICA 2015;100 (8):e302-e306 [PubMed]
  • Tonino SH, Mulkens CE, van Laar J, Derks IAM, Suo G, Croon-de Boer F, van Oers MHJ, Eldering E, Wang JY, Kater AP, Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia. LEUKEMIA LYMPHOMA 2015;56 (8):2439-2447 [PubMed]

2014

  • Kater AP, Eldering E, miR in CLL: more than mere markers of prognosis?. BLOOD 2014;124 (1):2-4 [PubMed]
  • Kater AP, Spiering M, Liu RD, Doreen te Raa G, Slinger E, Tonino SH, Beckers MM, Daenen S, Doorduijn JK, Lankheet NAG, Luijks DM, Eldering E, van Oers MHJ, Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study. LEUKEMIA RES 2014;38 (1):34-41 [PubMed]
  • Kater AP, Tonino SH, Egle A, Ramsay AG, How does lenalidomide target the chronic lymphocytic leukemia microenvironment?. BLOOD 2014;124 (14):2184-2189 [PubMed]
  • Lim KH, Thomas G, van Beers EJ, Hosman AE, Mourits MP, van Noesel CJM, Kater AP , Reinartz SM, Acute sinusitis and blindness as the first presentation of chronic lymphocytic leukaemia. NETH J MED 2014;72 (10):548-550 [PubMed]
  • te Raa GD, Malčiková J, Mraz M, Trbusek M, Le Garff-Tavernier M, Merle-Béral H, Greil R, Merkel O, Pospíšilová S, Lin K, Pettitt AR, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP, Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach. BRIT J HAEMATOL 2014;167 (4):565-569 [PubMed]
  • te Raa GD, Pascutti MF, García-Vallejo JJ, Reinen E, Remmerswaal EBM, ten Berge IJM, van Lier RAW, Eldering E, van Oers MHJ, Tonino SH, Kater AP, CMV-specific CD8(+) T-cell function is not impaired in chronic lymphocytic leukemia. BLOOD 2014;123 (5):717-724 [PubMed]

2013

  • de Weerdt I, Eldering E, van Oers MH, Kater AP, The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia. LEUKEMIA RES 2013;37 (7):838-847 [PubMed]
  • Hoogeboom R, van Kessel KPM, Hochstenbach F, Wormhoudt TA, Reinten RJA, Wagner K, Kater AP, Guikema JEJ, Bende RJ, van Noesel CJM, A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J EXP MED 2013;210 (1):59-70 [PubMed]
  • Jethwa A, Hüllein J, Stolz T, Blume C, Sellner L, Jauch A, Sill M, Kater AP, te Raa GD, Geisler C, van Oers M, Dietrich S, Dreger P, Ho AD, Paruzynski A, Schmidt M, von Kalle C, Glimm H, Zenz T, Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia. BRIT J HAEMATOL 2013;163 (4):496-500 [PubMed]
  • Kater AP, The half-life of guidelines for Waldenstrom's macroglobulinaemia; short stickiness for a sticky disease?. NETH J MED 2013;71 (2):52-53 [PubMed]
  • Lanasa MC, Kater AP, Shanafelt T, Fischer K, Highlights of the 7th young investigators' meeting on chronic lymphocytic leukemia. LEUKEMIA LYMPHOMA 2013;54 (8):1815-1816 [PubMed]
  • Lascano V, Guadagnoli M, Schot JG, Luijks DM, Guikema JEJ, Cameron K, Hahne M, Pals S, Slinger E, Kipps TJ, van Oers MHJ, Eldering E, Medema JP, Kater AP, Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model. BLOOD 2013;122 (24):3960-3963 [PubMed]
  • Oostvogels R, Minnema MC, van Elk M, Spaapen RM, te Raa GD, Giovannone B, Buijs A, van Baarle D, Kater AP , Griffioen M, Spierings E, Lokhorst HM, Mutis T, Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1. LEUKEMIA 2013;27 (3):642-649 [PubMed]
  • Pascutti MF, Jak M, Tromp JM, Derks IAM, Remmerswaal EBM, Thijssen R, van Attekum MHA, van Bochove GG, Luijks DM, Pals ST, van Lier RAW, Kater AP, van Oers MHJ, Eldering E, IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. BLOOD 2013;122 (17):3010-3019 [PubMed]
  • te Raa GD, Malcikova J, Pospisilova S, Trbusek M, Mraz M, Garff-Tavernier ML, Merle-Béral H, Lin K, Pettitt AR, Merkel O, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP, Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia. LEUKEMIA LYMPHOMA 2013;54 (8):1849-1853 [PubMed]
  • van den Broek EC, Kater AP , van de Schans SA, Karim-Kos HE, Janssen-Heijnen ML, Peters WG, Nooijen PT, Coebergh JW, Posthuma EF, Chronische lymfatische leukemie in Nederland: Trends in incidentie, behandeling en overleving (1989-2008). NED TIJDSCHR HEMATOL 2013;10:244-253

2012

  • Kater AP , Chamuleau ME, Posthuma W, Schipperus MR, Spiering M, van Oers MH, HOVON 109: de effectiviteit en veiligheid van eerstelijnsbehandeling van chronische lymfatische leukemie met chloorambucil, rituximab en lenalidomide bij oudere patienten en patienten met comorbiditeit; een fase I/II-studie. NED TIJDSCHR HEMATOL 2012;9:197
  • Kater AP, Shanafelt T, Fischer K, Wierda W, Highlights of the 6th Young Investigators' Meeting on chronic lymphocytic leukemia. LEUKEMIA LYMPHOMA 2012;53 (11):2312-2313 [PubMed]
  • Lapid O, van der Horst CM, Kater AP, Donor-Derived Fat Tissue As a Source for Lipofilling After Allogeneic Hematopoietic Cell Transplantation. J CLIN ONCOL 2012;30 (17):E154-E155 [PubMed]
  • Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP , Cymbalista F, Eichhorst B, Hallek M, Döhner H, Hillmen P, van Oers M, Gribben J, Ghia P, Montserrat E, Stilgenbauer S, Zenz T, ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. LEUKEMIA 2012;26 (7):1458-1461 [PubMed]
  • te Raa GD, Tonino SH, Remmerswaal EBM, van Houte AJ, Koene HR, van Oers MH, Kater AP, Chronic lymphocytic leukemia specific T-cell subset alterations are clone-size dependent and not present in monoclonal B lymphocytosis. LEUKEMIA LYMPHOMA 2012;53 (11):2321-2325 [PubMed]
  • te Raa GD, van Oers MH, Kater AP, Monoclonal B-cell lymphocytosis: Recommendations from the Dutch Working Group on CLL for daily practice. NETH J MED 2012;70 (5):236-241 [PubMed]
  • te Raa GD, van Oers MH, Kater AP, Monoklonale B-cellymfocytose: incidentie, risicostratificatie en aanbevelingen voor de dagelijkse praktijk. NED TIJDSCHR HEMATOL 2012;9:138
  • Tonino SH, van de Berg PJ, Yong SL, ten Berge IJ, Kersten MJ, van Lier RAW, van Oers MH, Kater AP, Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia. LEUKEMIA LYMPHOMA 2012;53 (9):1785-1794 [PubMed]
  • Tromp JM, Geest CR, Breij ECW, Elias JA, van Laar J, Luijks DM, Kater AP, Beaumont T, van Oers MHJ, Eldering E, Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia. CLIN CANCER RES 2012;18 (2):487-498 [PubMed]
  • van den Broek EC, Kater AP , van de Schans SAM, Karim-Kos HE, Janssen-Heijnen MLG, Peters WG, Nooijen PTGA, Coebergh JWW, Posthuma EFM, Chronic Lymphocytic Leukaemia in the Netherlands: Trends in incidence, treatment and survival, 1989-2008. EUR J CANCER 2012;48 (6):889-895 [PubMed]

2011

  • Fischer K, Shanafelt T, Kater AP, Highlights of the 5th Young Investigators' Meeting on chronic lymphocytic leukemia. LEUKEMIA LYMPHOMA 2011;52 (7):1391-1393 [PubMed]
  • Guadagnoli M, Kimberley F, Phan U, Cameron K, Vink P, Rodermond H, Eldering E, Kater A, van Eenennaam H, Medema JP, Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. BLOOD 2011;117 (25):6856-6865 [PubMed]
  • Kater AP, CLL: Nu werken aan behandeling van de toekomst. HEMATOL NEWS INT 2011;5 (6):21-23
  • Kater AP, Voor welke patiënten wordt ofatumumab vergoed?. HEMATOLOGIE ACTUEEL 2011;11 (5):onbekend
  • Kater AP , Wittebol S, Chamuleau MED, van Gelder M, J van Oers MH, Dutch guidelines for diagnosis and treatment of chronic lymphocytic leukaemia 2011. NETH J MED 2011;69 (10):422-429 [PubMed]
  • Kater AP , Wittebol S, Chamuleau ME, van Gelder M, van Oers MH, Richtlijnen diagnostiek en behandeling chronische lymfatische leukemie 2011. NED TIJDSCHR HEMATOL 2011;8:190-201
  • Mohr J, Helfrich H, Fuge M, Eldering E, Bühler A, Winkler D, Volden M, Kater AP, Mertens D, te Raa D, Döhner H, Stilgenbauer S, Zenz T, DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. BLOOD 2011;117 (5):1622-1632 [PubMed]
  • te Raa GD, Fischer K, Verweij W, van Houte AJ, Kater AP, Biesma DH, Use of the CD19 count in a primary care laboratory as a screening method for B-cell chronic lymphoproliferative disorders in asymptomatic patients with lymphocytosis. CLIN CHEM LAB MED 2011;49 (1):115-120 [PubMed]
  • Tonino SH. Targets for the treatment of drug resistant chronic lymphocytic leukemia. s.l.: s.n.; 2011. 175p. ISBN 9789090264820 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Oers MHJ; copromotor(s): Kater AP , Eldering E)
  • Tonino SH, Rijssenbeek AL, Oud ME, Pals ST, van Oers MH, Kater AP, Intracerebral Infiltration As the Unique Cause of the Clinical Presentation of Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. J CLIN ONCOL 2011;29 (34):E837-E839 [PubMed]
  • Tonino SH, van Laar J, van Oers MH, Wang JY, Eldering E, Kater AP, ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia. ONCOGENE 2011;30 (6):701-713 [PubMed]
  • Vos JMI, Bordbar A, Vet R, Pals ST, Kater AP, Waxing and waning intravascular large cell lymphoma with widespread organ infiltration. LEUKEMIA LYMPHOMA 2011;52 (4):705-708 [PubMed]

2010

  • Kater AP, Tonino SH, Standards for the treatment of relapsed chronic lymphocytic leukemia: a case-based study. CL LYMPH MYELOM LEUK 2010;10 (Suppl. 1):S34-S41 [PubMed]
  • Tonino SH, van Gelder M, Eldering E, van Oers MH, Kater AP, R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia. LEUKEMIA 2010;24 (3):652-654 [PubMed]
  • Tromp JM, Tonino SH, Elias JA, Jaspers A, Luijks DM, Kater AP , van Lier RAW, van Oers MHJ, Eldering E, Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering. ONCOGENE 2010;29 (36):5071-5082 [PubMed]
  • Zhang W, Kater AP, Widhopf GF 2nd, Chuang HY, Enzler T, James DF, Poustovoitov M, Tseng PH, Janz S, Hoh C, Herschman H, Karin M, Kipps TJ, B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. P NATL ACAD SCI USA 2010;107 (44):18956-18960 [PubMed]

2009

  • Enzler T, Kater AP, Zhang W, Widhopf GF 2nd, Chuang HY, Lee J, Avery E, Croce CM, Karin M, Kipps TJ, Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. BLOOD 2009;114 (20):4469-4476 [PubMed]
  • Kater AP , van Oers MHJ, De tyrosinekinaseremmer dasatinib voor behandeling van chemotherapie-refractaire chronische lymfatische leukemie: de D'ACCORD-studie. NED TIJDSCHR HEMATOL 2009;6 (8):317-320
  • Mous R, Jaspers A, Luijks DMP, Mellink CHM, van Oers MHJ, Kater AP , Eldering E, Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction. LEUKEMIA 2009;23 (7):1352-1355 [PubMed]
  • Zenz T, Mohr J, Eldering E, Kater AP, Bühler A, Kienle D, Winkler D, Dürig J, van Oers MHJ, Mertens D, Döhner H, Stilgenbauer S, miR-34a as part of the resistance network in chronic lymphocytic leukemia. BLOOD 2009;113 (16):3801-3808 [PubMed]

2008

  • Choi G, van den Borne MPJ, Visser CE, Kersten MJ, Kater AP, Invasive infections with a coagulase-negative staphylococcus in an immunocompromised patient: case report and review of the literature. ANN HEMATOL 2008;87 (9):771-772 [PubMed]
  • Hallaert DYH, Jaspers A, van Noesel CJ, van Oers MHJ, Kater AP, Eldering E, c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. BLOOD 2008;112 (13):5141-5149 [PubMed]
  • Kater AP , van Oers MHJ, De plaats van alemtuzumab bij de behandeling van chronische lymfatische leukemie. NED TIJDSCHR HEMATOL 2008;5 (6):236-244
  • Sonke GS, Ludwig I, van Oosten H, Baars JW, Meijer E, Kater AP, de Jong D, Poor outcomes of chronic active Epstein-Barr virus infection and hemophagocytic lymphohistiocytosis in non-Japanese adult patients. CLIN INFECT DIS 2008;47 (1):105-108 [PubMed]
  • Tonino SH, Spijker R, Luijks DMP, van Oers MHJ, Kater AP, No convincing evidence for a role of CD31-CD38 interactions in the pathogenesis of chronic lymphocytic leukemia. BLOOD 2008;112 (3):840-843 [PubMed]
  • van Dam IE, Kater AP , Hart W, van den Born BJH, Ernstige anemie door infectie met het Humaan parvovirus B19 bij een patiënt met een auto-immuun-hemolytische anemie en een B-cel-non-hodgkinlymfoom. NED TIJDSCHR GENEESKD 2008;152 (3):153-157 [PubMed]
  • van Gent R, Kater AP, Otto SA, Jaspers A, Borghans JAM, Vrisekoop N, Ackermans MAT, Ruiter AFC, Wittebol S, Eldering E, van Oers MHJ, Tesselaar K, Kersten MJ, Miedema F, In vivo Dynamics of Stable Chronic Lymphocytic Leukemia Inversely Correlate with Somatic Hypermutation Levels and Suggest No Major Leukemic Turnover in Bone Marrow. CANCER RES 2008;68 (24):10137-10144 [PubMed]

2007

  • Bouw J, Kater AP, van Tongeren J, Schultz MJ, Upper-airway obstruction instigated by Sweet's syndrome. MED SCI MONITOR 2007;13 (4):CS53-CS55 [PubMed]
  • Kater A, Henke MO, Rubin BK, The role of DNA and actin polymers on the polymer structure and rheology of cystic fibrosis sputum and depolymerization by gelsolin or thymosin beta 4. ANN NY ACAD SCI 2007;1112:140-153 [PubMed]
  • Kater AP, van Oers MHJ, Kipps TJ, Cellular immune therapy for chronic lymphocytic leukemia. BLOOD 2007;110 (8):2811-2818 [PubMed]
  • Smit LA, Hallaert DYH, Spijker R, de Goeij B, Jaspers A, Kater AP, van Oers MHJ, van Noesel CJM, Eldering E, Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. BLOOD 2007;109 (4):1660-1668 [PubMed]

2006

  • Dicker F, Kater AP, Prada CE, Fukuda T, Castro JE, Sun G, Wang JY, Kipps TJ, CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. BLOOD 2006;108 (10):3450-3457 [PubMed]
  • Kater AP. Novel apoptosis inducting strategies in chronic lymphocytic leukemia. S.l.: s.n.; 2006. 208p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Oers MHJ, Kipps TJ; copromotor(s): Eldering E)
  • Rubin BK, Kater AP, Goldstein AL, Thymosin beta4 sequesters actin in cystic fibrosis sputum and decreases sputum cohesivity in vitro. CHEST 2006;130 (5):1433-1440 [PubMed]

2005

  • Dicker F, Kater AP, Fukuda T, Kipps TJ, Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. BLOOD 2005;105 (8):3193-3198 [PubMed]
  • Kater AP, Dicker F, Mangiola M, Welsh K, Houghten R, Ostresh J, Nefzi A, Reed JC, Pinilla C, Kipps TJ, Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. BLOOD 2005;106 (5):1742-1748 [PubMed]
  • Kater AP , van Oers MHJ. Chronic lymphocytic leukemia: time for a risk-adapted approach in: Romero RM, editors. Trends in leukemia research. S.l.: Nova Science Publishers, Inc; 2005., p. 363-383
  • Mackus WJM, Kater AP , Grummels A, Evers LM, Hooijbrink B, Kramer MHH, Castro JE, Kipps TJ, van Lier RAW, van Oers MHJ, Eldering E, Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. LEUKEMIA 2005;19 (3):427-434 [PubMed]

2004

  • Kater AP, Evers LM, Remmerswaal EBM, Jaspers A, Oosterwijk MF, van Lier RAW, van Oers MHJ, Eldering E, CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. BRIT J HAEMATOL 2004;127 (4):404-415 [PubMed]
  • Kater AP, Remmerswaal EBM, Nolte MA, Eldering E, van Oers MHJ, van Lier RAW, Autologous cytomegalovirus-specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia. BRIT J HAEMATOL 2004;126 (4):512-516 [PubMed]

2003

  • Kater AP , van Oers MHJ, Chronische lymfatische leukemie: hoog tijd voor een op het risico afgestemd beleid. NED TIJDSCHR GENEESKD 2003;147 (3):104-110 [PubMed]

2002

  • Kater AP, Peppelenbosch MP, Brandjes DPM, Lumbantobing M, Dichotomal effect of the coumadin derivative warfarin on inflammatory signal transduction. CLIN DIAGN LAB IMMUN 2002;9 (6):1396-1397 [PubMed]
  • Kater AP , van der Lelie J, Levi M, Trombotische microangiopathie: trombocytopenie en hemolytische anemie. NED TIJDSCHR GENEESKD 2002;146 (49):2343-2347 [PubMed]
  • Kater AP , van Oers MHJ, Immunogentherapie. Bestrijding leukemie door activatie afweersysteem met behulp van CD70. ANALYSE (AMSTERDAM) 2002;- (oktober):240-242

2001

  • Schnog JB, Kater AP , Mac Gillavry MR, Duits AJ, Lard LR, van der Dijs FP, Brandjes DP, ten Cate H, van Eps LW, Rojer RA, Low adjusted-dose acenocoumarol therapy in sickle cell disease: a pilot study. AM J HEMATOL 2001;68 (3):179-183 [PubMed]

2000

  • Kater AP , Westermann AM , de Groot MR, von dem Borne AE, Kuijper EJ, Toxin-mediated haemolytic uraemic syndrome without diarrhoea. J INTERN MED 2000;248 (3):263-265 [PubMed]

1999

  • Kater AP , Heijboer H, Peters M, Vogels T, Prins MH, Heymans HS, Kwaliteit van leven bij kinderen met sikkelcelziekte in de regio Amsterdam. NED TIJDSCHR GENEESKD 1999;143 (41):2049-2053 [PubMed]
  • Kater AP , Prins MH, von Rosenstiel IA, Ottenkamp J, Peters M, Transient thrombocytopenia after cardiac surgery in infants with Down syndrome. J PEDIAT HEMATOL ONC 1999;21 (2):170-171 [PubMed]